Agios Pharmaceuticals (AGIO) Getting Somewhat Favorable News Coverage, Analysis Finds
Media headlines about Agios Pharmaceuticals (NASDAQ:AGIO) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Agios Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.8431127470038 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Agios Pharmaceuticals (AGIO) Rating Lowered to Strong Sell at BidaskClub (americanbankingnews.com)
- Analysts Expect Agios Pharmaceuticals, Inc. (AGIO) Will Post Quarterly Sales of $16.14 Million (americanbankingnews.com)
- Agios Pharmaceuticals (AGIO) vs. The Competition Head-To-Head Contrast (americanbankingnews.com)
- Agios Pharmaceuticals is Now Oversold (AGIO) – Nasdaq (nasdaq.com)
- Agios Pharmaceuticals: Updates To Thesis And A Look Toward 2018 – Seeking Alpha (seekingalpha.com)
A number of equities analysts have recently commented on AGIO shares. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Royal Bank of Canada started coverage on Agios Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price objective on the stock. Oppenheimer set a $83.00 target price on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Friday, November 17th. Credit Suisse Group raised their target price on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a report on Thursday, November 2nd. Finally, SunTrust Banks set a $80.00 target price on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company’s stock. Agios Pharmaceuticals has a consensus rating of “Buy” and an average price target of $75.70.
Shares of Agios Pharmaceuticals (NASDAQ AGIO) traded down $0.25 during trading hours on Friday, hitting $52.12. The company had a trading volume of 677,014 shares, compared to its average volume of 337,727. Agios Pharmaceuticals has a 1-year low of $39.24 and a 1-year high of $72.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.19. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The firm had revenue of $11.35 million during the quarter, compared to analyst estimates of $10.85 million. During the same quarter last year, the firm earned ($1.63) EPS. Agios Pharmaceuticals’s quarterly revenue was up 26.4% on a year-over-year basis. research analysts predict that Agios Pharmaceuticals will post -6.59 earnings per share for the current year.
In other Agios Pharmaceuticals news, insider Scott Biller sold 2,146 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $67.23, for a total transaction of $144,275.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $71.09, for a total value of $71,090.00. Following the sale, the director now owns 84,394 shares of the company’s stock, valued at approximately $5,999,569.46. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 162,746 shares of company stock valued at $11,082,396. 5.43% of the stock is owned by insiders.
WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/16/agios-pharmaceuticals-agio-getting-somewhat-favorable-news-coverage-analysis-finds.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.